# Fueling the Fire: How Glutamine Metabolism Sustains Leukemia Growth and Resistance

**Authors:** Giovannino Silvestri

PMC · DOI: 10.3390/biomed6010007 · 2026-02-17

## TL;DR

This paper reviews how glutamine metabolism supports leukemia growth and resistance, and explores strategies to target it for treatment.

## Contribution

A detailed synthesis of glutamine metabolism's role in leukemia and therapeutic strategies to overcome resistance.

## Key findings

- Leukemic cells strongly depend on glutamine for energy and biosynthesis.
- Glutamine addiction is reinforced by oncogenic signaling and microenvironmental adaptation.
- Therapies targeting glutamine show promise but face challenges like metabolic plasticity and toxicity.

## Abstract

Glutamine metabolism has emerged as one of the most critical bioenergetic and biosynthetic programs sustaining leukemic cell growth, survival, stemness and therapeutic resistance. In both acute and chronic leukemias, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), malignant cells display a strong dependency on extracellular glutamine to support mitochondrial respiration, anabolic biosynthesis and redox homeostasis. This dependency is reinforced by oncogenic signaling networks, post-transcriptional metabolic regulation and microenvironmental adaptation within the bone marrow niche. Therapeutic strategies targeting glutamine utilization, including glutaminase inhibition, transporter blockade and enzymatic glutamine depletion, have demonstrated robust antileukemic activity in preclinical models, and early clinical efforts have begun to explore glutamine-directed interventions in myeloid neoplasms. However, metabolic plasticity, microenvironment-derived nutrient buffering and systemic toxicity remain significant limitations to clinical translation. This review provides a detailed synthesis of the biochemical framework of glutamine metabolism in leukemia, the molecular mechanisms enforcing glutamine addiction, the downstream functional consequences on proliferation, redox balance and leukemic stem cell biology, the current landscape of therapeutic strategies and emerging directions aimed at overcoming resistance and improving clinical efficacy.

## Linked entities

- **Diseases:** leukemia (MONDO:0004355), acute myeloid leukemia (MONDO:0015667), acute lymphoblastic leukemia (MONDO:0004967)

## Full-text entities

- **Genes:** GPM6A (glycoprotein M6A) [NCBI Gene 2823] {aka GPM6, M6A}, ASNS (asparagine synthetase (glutamine-hydrolyzing)) [NCBI Gene 440] {aka ASNSD, TS11}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, Gls (glutaminase) [NCBI Gene 14660] {aka 6330442B14, B230365M23Rik}, FLT3 (fms related receptor tyrosine kinase 3) [NCBI Gene 2322] {aka CD135, FLK-2, FLK2, STK1}, NOTCH1 (notch receptor 1) [NCBI Gene 4851] {aka AOS5, AOVD1, TAN1, hN1}, TXK (TXK tyrosine kinase) [NCBI Gene 7294] {aka BTKL, PSCTK5, PTK4, RLK, TKL}, CYCS (cytochrome c, somatic) [NCBI Gene 54205] {aka CYC, HCS, THC4}, SLC7A5 (solute carrier family 7 member 5) [NCBI Gene 8140] {aka 4F2LC, CD98, D16S469E, E16, LAT1, MPE16}, SLC3A2 (solute carrier family 3 member 2) [NCBI Gene 6520] {aka 4F2, 4F2HC, 4T2HC, CD98, CD98HC, MDU1}, TXN (thioredoxin) [NCBI Gene 7295] {aka TRDX, TRX, TRX1, TXN1, Trx80}, ATF4 (activating transcription factor 4) [NCBI Gene 468] {aka CREB-2, CREB2, TAXREB67, TXREB}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, EPAS1 (endothelial PAS domain protein 1) [NCBI Gene 2034] {aka ECYT4, HIF2A, HLF, MOP2, PASD2, bHLHe73}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, GLS (glutaminase) [NCBI Gene 2744] {aka AAD20, CASGID, DEE71, EIEE71, GAC, GAM}, SLC1A5 (solute carrier family 1 member 5) [NCBI Gene 6510] {aka AAAT, ASCT2, ATBO, M7V1, M7VS1, R16}, IDH2 (isocitrate dehydrogenase (NADP(+)) 2) [NCBI Gene 3418] {aka D2HGA2, ICD-M, IDH, IDH-2, IDHM, IDP}, GLUL (glutamate-ammonia ligase) [NCBI Gene 2752] {aka DEE116, GLNS, GS, PIG43, PIG59}, IGF2BP2 (insulin like growth factor 2 mRNA binding protein 2) [NCBI Gene 10644] {aka IMP-2, IMP2, VICKZ2}, AANAT (aralkylamine N-acetyltransferase) [NCBI Gene 15] {aka DSPS, SNAT}, IDH1 (isocitrate dehydrogenase (NADP(+)) 1) [NCBI Gene 3417] {aka HEL-216, HEL-S-26, IDCD, IDH, IDP, IDPC}
- **Diseases:** chromosomal abnormalities (MESH:D002869), cancer (MESH:D009369), pancreatitis (MESH:D010195), injury to (MESH:D014947), myeloid disease (MESH:D007951), chronic lymphocytic leukemia (MESH:D015451), mitochondrial (MESH:D028361), AML (MESH:D015470), hematologic malignancies (MESH:D019337), Hypoxia (MESH:D000860), hypoxic (MESH:D002534), T-cell acute lymphoblastic leukemia (MESH:D054218), infection (MESH:D007239), T (MESH:D001260), ALL (MESH:D054198), Toxicity (MESH:D064420), Leukemia (MESH:D007938)
- **Chemicals:** lactate (MESH:D019344), nitrogen (MESH:D009584), venetoclax (MESH:C579720), arsenic trioxide (MESH:D000077237), carbon (MESH:D002244), TCA (MESH:D014233), gilteritinib (MESH:C000609080), 2-HG (MESH:C019417), phosphoribosyl pyrophosphate (MESH:D010754), oxygen (MESH:D010100), ammonia (MESH:D000641), branched-chain amino acid (MESH:D000597), Glutamate (MESH:D018698), asparagine (MESH:D001216), leucine (MESH:D007930), purines (MESH:D011687), nucleotide (MESH:D009711), oxaloacetate (MESH:D062907), quizartinib (MESH:C544967), aspartate (MESH:D001224), amino acid (MESH:D000596), serine (MESH:D012694), fatty acid (MESH:D005227), FAO (-), alpha-KG (MESH:D007656), sodium (MESH:D012964), carbamoyl phosphate (MESH:D002221), midostaurin (MESH:C059539), glucose (MESH:D005947), azacitidine (MESH:D001374), CB-839 (MESH:C000593334), ROS (MESH:D017382), ATP (MESH:D000255), GSH (MESH:D005978), citrate (MESH:D019343), Glutamine (MESH:D005973), pyrimidines (MESH:D011743), homoharringtonine (MESH:D000077863), lipid (MESH:D008055)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** glutamine from glutamate, serine-glycine
- **Cell lines:** LSC — Rattus norvegicus (Rat), Spontaneously immortalized cell line (CVCL_9U29)

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12906304/full.md

---
Source: https://tomesphere.com/paper/PMC12906304